Clinical Outcomes Following the Use of Archived Proviral HIV-1 DNA Genotype to Guide Antiretroviral Therapy Adjustment

Persistence of HIV-1 drug resistance mutations in proviral DNA following virologic failure of Efavirenz-containing antiretroviral regimens

(2019) Justin De La Cruz et al.   Open Forum Infectious Diseases

Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I

(2019) Kristen Andreatta et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Human Immunodeficiency Virus Drug Resistance: 2018 Recommendations of the International Antiviral Society–USA Panel

(2018) Huldrych F Günthard et al.   CLINICAL INFECTIOUS DISEASES

OUP accepted manuscript

(2018)   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Interest of proviral HIV-1 DNA genotypic resistance testing in virologically suppressed patients candidate for maintenance therapy

(2018) C. Allavena et al.   JOURNAL OF VIROLOGICAL METHODS

Analysis of drug resistance mutations in whole blood DNA from HIV-1 infected patients by single genome and ultradeep sequencing analysis

(2018) Alma Sotillo et al.   JOURNAL OF VIROLOGICAL METHODS

Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study

(2018) Lene Ryom et al.   Lancet HIV

Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial

(2017) Frank A. Post et al.   HIV CLINICAL TRIALS

Future technologies for monitoring HIV drug resistance and cure

(2017) Urvi M. Parikh et al.   Current Opinion in HIV and AIDS

Inflammation, immune activation, and cardiovascular disease in HIV

(2016) Eric Nou et al.   AIDS

Clinical Outcomes of Virologically-Suppressed Patients with Pre-existing HIV-1 Drug Resistance Mutations Switching to Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in the SPIRIT Study*

(2016) Danielle P. Porter et al.   HIV CLINICAL TRIALS

Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA

(2016) Mauro Zaccarelli et al.   JOURNAL OF CLINICAL VIROLOGY

Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study

(2016) Kathleen Squires et al.   Lancet HIV

Long-Range HIV Genotyping Using Viral RNA and Proviral DNA for Analysis of HIV Drug Resistance and HIV Clustering

(2015) Vlad Novitsky et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

(2015) Paul E Sax et al.   LANCET

Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study

(2015) Jean-Michel Molina et al.   Lancet HIV

HIV Drug Resistance Mutations in Proviral DNA from a Community Treatment Program

(2015) Anne Derache et al.   PLoS One

Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor–Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1

(2014) Jeffrey L. Lennox et al.   ANNALS OF INTERNAL MEDICINE

Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia

(2011) M. Wirden et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Bone Disease in HIV Infection: A Practical Review and Recommendations for HIV Care Providers

(2010) Grace A. McComsey et al.   CLINICAL INFECTIOUS DISEASES